Stock Ratings / Health Care / ELAB / forecast

REVB (49) PPCB (36) BDRX (48) SILO (19) ⌘ Pro Terminal →

PMGC Holdings Inc. (ELAB) 12-Month Stock Forecast & Price Target Cone

Q: What is ELAB's 12-month stock price target?

PMGC Holdings Inc. (ELAB) carries a 12-month consensus base price target of $2.38 (-9.8% from $2.64), with a bull-case target of $1566.43 and a bear-case floor of $1.86.

Q: Is ELAB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ELAB D- (Sell — SELL) with an RQD Confidence score of 36/100.

$2.64 +2.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.65

PMGC Holdings Inc. (ELAB) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.65 (+0.30%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELAB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (36/100 Composite)

🔍 WHY ELAB SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.08-10.1% Next Q

Q2 (-2Q)

Grade D$2.77-2.2% Next Q

Q3 (-1Q)

Grade E$2.71-2.6% Next Q

Current

Grade D-$2.64-8.3% Hist 90D α

Trajectory: D (44) → D- (36)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELAB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELAB currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.05) and Max Pain ($2.77) forces dealer call-delta covering toward $1,566.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ELAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 36%NO 64%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ELAB Position Size: $10,000

Shares at $2.64: 3787.9 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.86

$7,045

$-2,955 (-29.5%)

12M Consensus BaseTarget $2.38

$9,015

$-985 (-9.8%)

12M Bull Case BreakoutTarget $1,566.43

$5,933,447

+$5,923,447 (+59234.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$1,472	69%	B
JP MorganUS Large-Cap Research	SELL	$2	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELAB)

✓Walkthrough of ELAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ELAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -89.27%⚡ TESTING RESISTANCE

2026-10-30O $2.64H $2.70L $2.51C $2.64VOL 7.5K

RES: $3.60SUP: $-2.57SMA50: $4.05SMA200: $35.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELAB Butterfly Map → + Track ELAB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ELAB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELAB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ELAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELAB)

Health Care Rank #805 of 1016 ⚔️ REVB vs ELAB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELAB vs. REVB, PPCB, BDRX, SILO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PMGC Holdings Inc. (ELAB) ranks #805 by composite RQD confidence (36/100, grade D-) and #995 by equity capitalization ($2.1M). Within this direct 5-issuer industry benchmark cohort, ELAB leads on earnings valuation at N/A trailing P/E, while ELAB leads on capital efficiency and profitability with -35.0% ROIC and 31.4% gross margin. REVB currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ELAB at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ELAB ACTIVE PMGC Holdings Inc.	D-	36/100	—	31.4%	-35.0%	+2.72%	$2.1M	Benchmark Subject
REVB Revelation Biosciences Inc.	D	49/100	—	—	-35.0%	+0.81%	$2.1M	/revb-vs-elab →
PPCB Propanc Biopharma Inc.	D-	36/100	—	—	-35.0%	0.00%	$2.2M	/ppcb-vs-elab →
BDRX Biodexa Pharmaceuticals plc American Depositary Shs	D	48/100	—	—	—	-5.80%	$2.0M	/bdrx-vs-elab →
SILO Silo Pharma Inc.	E	19/100	—	38.6%	-35.0%	-6.72%	$2.4M	/silo-vs-elab →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001840563

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PMGC Holdings Inc. (ELAB) reported GAAP revenue of $590.1K (N/A vs. FY2024 revenue of $0 , and -65.5% cumulative change since FY2023) , GAAP net income of -$7.7M, operating cash flow of -$5.9M, and free cash flow of -$6.4M (-16.0% YoY). On the balance sheet, ELAB closed FY2025 with $12.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$590.1K	-$7.7M	-$5.9M	-$6.4M	$12.9M	—
FY2024 (FY)	2024-12-31	$0	-$6.2M	-$5.5M	-$5.5M	$9.0M	—
FY2023 (FY)	2023-12-31	$1.7M	-$4.3M	-$4.6M	-$4.6M	—	—

3. ELAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, PMGC Holdings Inc. (NASDAQ: ELAB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.64 (+2.72% 1D, market cap $2.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELAB ranks #805 in composite RQD confidence.

How does ELAB compare to REVB and PPCB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAB carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 31.4%, and ROIC of -35.0%. By comparison, REVB (Revelation Biosciences Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and PPCB (Propanc Biopharma Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.2M). Among the 5-stock peer group, ELAB leads on earnings multiple (N/A) while ELAB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ELAB?

Per ELAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840563), PMGC Holdings Inc. generated $590.1K in revenue, -$7.7M in net income, and -$6.4M in free cash flow against $12.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ELAB trading relative to its 50-day, 200-day, and 52-week technical levels?

ELAB last traded at $2.64 (+2.72% on volume of 6,711 shares), positioning the stock -34.81% below its 50-day simple moving average ($4.05) and -92.57% below its 200-day simple moving average ($35.54). Across its 52-week range of $2.51 to $1,491.84, ELAB sits at the 0.0% percentile with a 14-day RSI of 25.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.31 to $2.97).

ELAB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ELAB's 12-month stock price target?

PMGC Holdings Inc. (ELAB) carries a 12-month consensus base price target of $2.38 (-9.8% from $2.64), with a bull-case target of $1566.43 and a bear-case floor of $1.86.

Is ELAB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ELAB D- (Sell — SELL) with an RQD Confidence score of 36/100.

Direct Sub-Reports: ELAB RQD Cockpit ELAB 12M Forecast ELAB Earnings & Move ELAB Dividends & DRIP ELAB Insiders & 13F ELAB Whale Options ELAB Profit Sankey ELAB News & Why